Huons BioPharma attracts $132 mil from China's Imeik Technology Development Subsidiary of Huons Global aims to enter Chinese botulinum toxin market
Translated by Kim So-in 공개 2021-09-24 08:09:51
이 기사는 2021년 09월 24일 08:07 thebell 에 표출된 기사입니다.
Huons BioPharma, a subsidiary of Huons Global, has attracted 155.4 billion won ($132 million) from China’s Imeik Technology Development, gaining a foothold in the rapidly botulinum toxin market in China.Huons BioPharma received a total of 155.4 billion won from Imeik Technology Development on September 16 after the two companies signed an agreement in June. Imeik Technology Development, which manufactures and distributes biomedical products, aims to enter the botulinum toxin market there through the latest partnership.
Imeik Technology Development has become the second largest shareholder of Huons BioPharma by securing a 25.4% stake in the Korean company. Huons Global remains to be the largest shareholder, although its stake has been reduced to 74.6%.
Huons Global teamed up with Imeik Technology Development about two months after it established Huons BioPharma through a split-off in April. Huons Global is speeding up its efforts to expand its business in China by completing the deal process within six months.
Huons BioPharma’s botulinum toxin product, Hutox, is currently under preparation to launch phase 3 clinical trials in China.
Huons BioPharma targets the Chinese market through the latest partnership, which has high growth potential and is relatively less competitive. The Chinese botulinum toxin market is expected to reach 2 trillion won by 2025, about four times bigger than that of Korea.
Huons Global and Huons BioPharma expect it will take about three to four years for Hutox to enter the Chinese market after completing phase 3 clinical trials and obtaining approval from the China's National Medical Products Administration (NMPA). Currently in China, botulinum toxin formulations produced by U.S.’ Allergan, Korea’s Hugel, France’s Ipsen, and a Chinese state-run research institute are on the market.
“Considering all circumstances, we will be able to create a three-way battle or better, thanks to product competitiveness, even if we are a late comer to the market,” said an official at Huons Global. “We will actively utilize our partnership with Imeik to ensure that our clinical trials and business operations go smoothly.” (Reporting by Eun-su Choi)
< 저작권자 ⓒ 자본시장 미디어 'thebell', 무단 전재, 재배포 및 AI학습 이용 금지 >
best clicks
최신뉴스 in 전체기사
-
- 베니스 비엔날레, 30년만에 두발로 선 '곽훈'의 의미
- [대기업 프로스포츠 전술전략]'모기업발 숙제' 엔씨다이노스, 당분간 긴축 불가피
- 하이브, '민희진 없는' 어도어 경쟁력 입증할까
- SK 오너가 3세 최성환의 '승부수'
- 어느 수집가의 꿈 '이건희 컬렉션'
- [코스닥 리빌딩 리포트]'비상장사 투자 손실' 비투엔, 신사업 '삐걱'
- 유진운용, 공모주-미국 장기채 혼합 펀드 출시
- [우리은행 글로벌그룹 대수술]연체율 치솟는 캄보디아 법인, 방카슈랑스 돌파구 될까
- [우리은행 글로벌그룹 대수술]쿠펜대출 발목잡힌 인니법인, 타개책 '파생상품 확장'
- [우리은행 글로벌그룹 대수술]신한베트남 게섰거라…WM 특화점포로 드라이브